Revelation Biosciences, Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is ...
Tumor necrosis factor (TNF)-alpha ... in which 15 patients with mild-to-severe AD were treated for 6 months. We administered etanercept, 25-50 mg, once weekly by perispinal administration.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback